As of 2026-09-30, the EV/EBITDA ratio of NGM Biopharmaceuticals Inc (NGM) is -0.49. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NGM's latest enterprise value is 72.71 mil USD. NGM's TTM EBITDA according to its financial statements is -149.48 mil USD. Dividing these 2 quantities gives us the above NGM EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 5.8x - 8.2x | 6.9x |
| Forward P/E multiples | 6.7x - 9.9x | 7.8x |
| Fair Price | (11.37) - (14.09) | (12.45) |
| Upside | -838.1% - -1014.9% | -908.5% |
| Date | EV/EBITDA |